Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRBP Stock Forecast 2026-2027
$9.55
Current Price
$176.94M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRBP Price Targets
+444.5%
To High Target of $52.00
+266.5%
To Median Target of $35.00
+78.0%
To Low Target of $17.00
CRBP Price Momentum
+3.2%
1 Week Change
+24.0%
1 Month Change
+14.1%
1 Year Change
+17.3%
Year-to-Date Change
-53.6%
From 52W High of $20.56
+34.1%
From 52W Low of $7.12
📊 TOP ANALYST CALLS
Did CRBP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Corbus Pharmaceuticals is one of their latest high-conviction picks.
Latest CRBP Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CRBP has a bullish consensus with a median price target of $35.00 (ranging from $17.00 to $52.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $9.55, the median forecast implies a 266.5% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jeff Jones at Oppenheimer, projecting a 444.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRBP Analyst Ratings
9
Buy
0
Hold
0
Sell
CRBP Price Target Range
Low
$17.00
Average
$35.00
High
$52.00
Current: $9.55
Latest CRBP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRBP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 23, 2026 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $34.00 |
| Jun 17, 2026 | Oppenheimer | Jeff Jones | Outperform | Maintains | $52.00 |
| May 27, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| May 26, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 22, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| May 13, 2026 | Jefferies | Buy | Maintains | $N/A | |
| May 13, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 13, 2026 | Guggenheim | Buy | Reiterates | $N/A | |
| Apr 29, 2026 | Guggenheim | Buy | Initiates | $N/A | |
| Mar 10, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| Nov 13, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Oct 20, 2025 | Wedbush | Outperform | Maintains | $N/A | |
| Oct 20, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 17, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 6, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 7, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| May 7, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 7, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 12, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 11, 2025 | Jefferies | Buy | Maintains | $N/A |
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Competitors
The following stocks are similar to Corbus Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CRBP
Corbus Pharmaceuticals
mkt cap
171.38M
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Financial Data
Corbus Pharmaceuticals Holdings, Inc. has a market capitalization of $176.94M with a P/E ratio of -1.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -66.7%.
Valuation Metrics
Market Cap
$176.94M
Enterprise Value
$34.37M
P/E Ratio
-1.6x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+78.1%
Current Ratio
7.9x
Debt/Equity
1.0x
ROE
-66.7%
ROA
-39.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Business Model
About Corbus Pharmaceuticals Holdings, Inc.
What They Do
Develops therapies for oncology and obesity.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, generating revenue through the development and commercialization of targeted therapies. It invests in advanced clinical trials for its drug candidates, which are designed to address unmet medical needs in cancer and obesity, with the potential for significant market opportunities upon successful approval.
Additional Information
Corbus Pharmaceuticals is located in Norwood, Massachusetts, and focuses on innovative treatments utilizing well-understood biological pathways. Its key drug candidates include CRB-701, CRB-601, and CRB-913, which are in various stages of development for solid tumors and obesity. The company's emphasis on precision medicine aims to enhance patient outcomes in critical therapeutic areas.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
36
CEO
Dr. Yuval Cohen Ph.D.
Country
United States
IPO Year
2014
Website
www.corbuspharma.comCorbus Pharmaceuticals Holdings, Inc. (CRBP) Latest News & Analysis
Latest News
Quick Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) appointed Dr. Leonardo Viana Nicacio as part of its focus on developing therapies for oncology and obesity.
Why It Matters
The appointment of Dr. Nicacio may signal a strategic shift or boost in expertise for Corbus, potentially impacting its drug development and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Corbus Pharmaceuticals CEO Yuval Cohen discussed upcoming clinical readouts and development plans for its two lead drug candidates at a Jefferies event.
Why It Matters
Corbus Pharmaceuticals' updates on clinical timelines and drug development can impact stock performance, signaling potential value creation or risks based on upcoming results.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) is concentrating its CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer linked to HPV, as discussed during an ASCO event.
Why It Matters
Corbus Pharmaceuticals' focus on CRB-701 for HPV-related oropharyngeal cancers highlights a targeted approach, potentially enhancing its market position and attracting investor interest in oncology advancements.
Source: MarketBeat
Market Sentiment:
Neutral
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
1 month ago
Quick Summary
Corbus Pharmaceuticals Holdings, Inc. (CRBP) shared important insights from its event focused on head and neck squamous cell carcinoma (HNSCC) with key opinion leaders.
Why It Matters
Insights from the HNSCC KOL event may indicate future drug developments or market strategies for Corbus, potentially impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Corbus Pharmaceuticals (CRBP) shared updates on clinical data from its Phase 1/2 study of CRB-701 at ASCO, indicating progress in its drug development pipeline.
Why It Matters
The update on CRB-701's clinical data signals progress in Corbus Pharmaceuticals' drug development, potentially impacting stock performance and future revenue prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Corbus Pharmaceuticals (NASDAQ: CRBP) announced promising Phase 1/2 data for CRB-701, targeting HPV-driven cancers. Results will be presented at the ASCO Annual Meeting from May 29 to June 2, 2026.
Why It Matters
The positive data from Corbus Pharmaceuticals' clinical study for CRB-701 indicates potential market value and growth in treating specific cancers, which could boost investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CRBP Stock
What is Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) stock forecast for 2027?
Based on our analysis of 8 Wall Street analysts, Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a median price target of $35.00. The highest price target is $52.00 and the lowest is $17.00.
Is CRBP stock a good investment in 2027?
According to current analyst ratings, CRBP has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRBP stock?
Wall Street analysts predict CRBP stock could reach $35.00 in the next 12 months. This represents a 266.5% increase from the current price of $9.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Corbus Pharmaceuticals Holdings, Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, generating revenue through the development and commercialization of targeted therapies. It invests in advanced clinical trials for its drug candidates, which are designed to address unmet medical needs in cancer and obesity, with the potential for significant market opportunities upon successful approval.
What is the highest forecasted price for CRBP Corbus Pharmaceuticals Holdings, Inc.?
The highest price target for CRBP is $52.00 from Jeff Jones at Oppenheimer, which represents a 444.5% increase from the current price of $9.55.
What is the lowest forecasted price for CRBP Corbus Pharmaceuticals Holdings, Inc.?
The lowest price target for CRBP is $17.00 from at , which represents a 78.0% increase from the current price of $9.55.
What is the overall CRBP consensus from analysts for Corbus Pharmaceuticals Holdings, Inc.?
The overall analyst consensus for CRBP is bullish. Out of 8 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are CRBP stock price projections?
Stock price projections, including those for Corbus Pharmaceuticals Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 5:46 PM UTC